安罗替尼联合化疗在甲状腺鳞状细胞癌中的临床获益和安全性分析  

Safety and outcomes of anlotinib based chemotherapy in primary squamous cell thyroid carcinoma

作　　者：潘华远 汪菁 岳健 李静[4] 胡蕾 叶磊[1] 王圣应 Pan Huayuan;Wang Jing;Yue Jian;Li Jing;Hu Lei;Ye Lei;Wang Shengying(Department of Ultrasound Medicine,the First Affiliated Hospital of University of Science and Technology of China West District(Anhui Provincial Cancer Hospital),Hefei 230031,China;Department of Breast Surgery Ward 2,the First Affiliated Hospital of University of Science and Technology of China West District(Anhui Provincial Cancer Hospital),Hefei 230031,China;Department of Breast Diseases of Gaozhou People’s Hospital,Maoming 525200,China;Department of Chest tumor Ward 2,the First Affiliated Hospital of University of Science and Technology of China West District(Anhui Provincial Cancer Hospital),Hefei 230031,China;Department of Ultrasound Medicine,the First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230031,China)

机构地区：[1]中国科学技术大学附属第一医院西区(安徽省肿瘤医院)超声医学科,合肥230031 [2]中国科学技术大学附属第一医院西区(安徽省肿瘤医院)乳腺外科二病区,合肥230031 [3]高州市人民医院乳腺病科,茂名525200 [4]中国科学技术大学附属第一医院西区(安徽省肿瘤医院)胸部肿瘤二病区,合肥230031 [5]中国科学技术大学附属第一医院(安徽省立医院)超声医学科,合肥230031

出　　处：《中华内分泌外科杂志（中英文）》2024年第6期830-834,共5页Chinese Journal of Endocrine Surgery

基　　金：中央高校基本科研业务费专项资金资助(科大新医学联合基金培育项目)(YD9110002030)。

摘　　要：目的探寻以安罗替尼联合化疗策略作为甲状腺鳞状细胞癌(PSTC)一线治疗的有效性和安全性。方法纳入2018年1月至2023年7月就诊中国科学技术大学附属第一医院甲乳外科首诊未接受抗肿瘤治疗且接受安罗替尼联合化疗方案的PSTC患者。被纳入患者接受2~6个周期的安罗替尼治疗,12 mg/次,1~14 d/21 d。化疗方案包括多西紫杉醇、卡培他滨或多西紫杉醇联合卡铂/卡培他滨。分析终点包括客观反应率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)和肿瘤特异生存期(DSS)。结果共有14例入组。最终1例完全缓解(CR),7例部分缓解(PR),5例出现疾病稳定(SD),1例疾病进展(PD),最佳ORR为57.1%(8/14),DCR为64.3%(9/14)。中位PFS为3.7个月,中位DSS为7.8个月。约71.4%(10/14)的患者出现不良事件(AE)。大多数AEs是可耐受的,1例行剂量调整,没有患者因AE不能耐受而停药。结论以安罗替尼为基础的化疗作为一线治疗对治疗PSTC患者是一种安全有效的干预措施。ObjectiveTo assess the efficacy and safety profile of anlotinib-based chemotherapy as the primary treatment modality for PSTC.MethodsThis study included patients with locally advanced or metastatic PSTC who had not received any prior anti-tumor treatments between Jan.2018 and Jul.2023 at the Department of Breast Surgery,First Affiliated Hospital of the University of Science and Technology of China.The enrolled patients were administered anlotinib at a dose of 12 mg every 1 to 14 days for a total duration of 21 days,across 2 to 6 cycles.The chemotherapy regimen comprised paclitaxel,capecitabine,or docetaxel in combination with carboplatin or capecitabine.The assessed endpoints included the objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS),and disease-specific survival(DSS).ResultsFourteen patients were recruited for the study.Among them,one patient achieved a CR,seven patients attained a PR,five patients exhibited SD,and one patient presented with PD.The highest recorded ORR was 57.1%,accompanied by a DCR of 64.3%.The median PFS was 3.7 months,and the median DSS was 7.8 months.Notably,approximately 71.4%of patients experienced adverse events(AEs).The majority of AEs were manageable,with only one patient requiring a dosage adjustment,and no patients discontinued medication due to AEs.ConclusionsAnlotinib-based chemotherapy,as the primary therapeutic approach,demonstrates safety and efficacy in managing patients diagnosed with PSTC.

关 键 词：甲状腺鳞状细胞癌 安罗替尼 靶向治疗 甲状腺 

分 类 号：R736.1[医药卫生—肿瘤]